Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Polydex Pharmaceuticals Ltd is engaged in the development, manufacturing, and marketing of biotechnology-based products for the human pharmaceutical market. In addition, it also engaged in the manufacture and sale of veterinary pharmaceutical products and specialty chemicals. It focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. Geographically sale of the products can be seen amplifying in the region of Europe, United States, Canada, and other countries of which the United States region accounts for the larger share of revenue.
Toronto, ON, M1L 2H5, Canada